Tag Archives: Cancer

Healthcare Systems in Europe "Failing Patients"

By Reflector, Brussels correspondent. Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault in Dublin, Ireland, last week, at a conference organized under the auspices of the Irish Presidency of the European Union and featuring a galaxy of Irish and European stars […]
Posted in Europe, Guest Blog, healthcare, Op-Ed | Also tagged , , , , , | 1 Comment

Patients on the Picket Line

Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
Posted in Biotech, FDA, healthcare, Legal, Market Access, Regulatory, Safety | Also tagged , , , , , , , , , , , | Leave a comment

Is There a Global Policy Gap on Cancer?

Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day.  Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the […]
Posted in Global | Also tagged , , | Leave a comment

Future Boom in Chronic Cancer Patients Likely to Change the Face of Disease, suggest ASCO Findings

Patients who live for many years following a cancer diagnosis will likely require additional support, and a whole new kind of follow-up care. by John Otrompke Dramatic developments in studies of patients with advanced cancer suggest that the day may be coming within our lifetime when most cancer patients will experience the disease as a […]
Posted in Strategy | Also tagged , | 1 Comment

First Orphan Launch a Challenge for AstraZeneca

Four months after AstraZeneca received FDA approval for vandetanib, a treatment for inoperable medullary thyroid cancer, the company announced the drug’s trade name: Caprelsa. FDA said other proposed names – Zactima, for example – too closely resembled other currently marketed proprietary names. Getting FDA approval on a brand name for vandetanib, AstraZeneca’s very first orphan drug, […]
Posted in FDA, Marketing, patient education, Safety, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta